Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 613

1.

The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.

Achilla E, McCrone P.

Appl Health Econ Health Policy. 2013 Apr;11(2):95-106. doi: 10.1007/s40258-013-0016-2. Review.

PMID:
23494934
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Laux G, Heeg B, van Hout BA, Mehnert A.

Pharmacoeconomics. 2005;23 Suppl 1:49-61.

PMID:
16416761
4.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
5.
6.

Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.

Yang YK, Tarn YH, Wang TY, Liu CY, Laio YC, Chou YH, Lee SM, Chen CC.

Psychiatry Clin Neurosci. 2005 Aug;59(4):385-94. Erratum in: Psychiatry Clin Neurosci. 2005 Oct;59(5):625-6. Tarn, Yeng Hui [corrected to Tarn, Yen-Huei].

7.

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.

De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, Lecompte D, Peuskens J.

Pharmacoeconomics. 2005;23 Suppl 1:35-47.

PMID:
16416760
8.

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.

Pharmacoeconomics. 2005;23 Suppl 1:75-89.

PMID:
16416763
9.

[Pharmacoeconomic review of the use of injectable long-acting risperidone].

Bartkó G, Fehér L.

Neuropsychopharmacol Hung. 2005 Dec;7(4):199-207. Review. Hungarian.

PMID:
16496485
10.

Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.

Tempest M, Sapin C, Beillat M, Robinson P, Treur M.

J Ment Health Policy Econ. 2015 Dec;18(4):185-200.

PMID:
26729007
11.

Risperidone. A pharmacoeconomic review of its use in schizophrenia.

Foster RH, Goa KL.

Pharmacoeconomics. 1998 Jul;14(1):97-133. Review.

PMID:
10182198
12.

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ.

Pharmacoeconomics. 2005;23(3):299-314.

PMID:
15836010
13.

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.

Edwards NC, Pesa J, Meletiche DM, Engelhart L, Thompson AK, Sherr J, Dirani R.

Curr Med Res Opin. 2008 Dec;24(12):3341-55. doi: 10.1185/03007990802490512 . Review.

PMID:
18954497
14.

The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.

Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ.

Health Technol Assess. 2009 Sep;13(41):1-190, 215-357, iii-iv. doi: 10.3310/hta13410. Review.

15.
16.

Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.

Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJ.

J Clin Psychiatry. 2013 Jun;74(6):568-75. doi: 10.4088/JCP.12r08167. Epub 2013 Apr 19. Review.

17.

Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.

Zeidler J, Mahlich J, Greiner W, Heres S.

Appl Health Econ Health Policy. 2013 Oct;11(5):509-21. doi: 10.1007/s40258-013-0050-0. Erratum in: Appl Health Econ Health Policy. 2013 Dec;11(6):689.

PMID:
23975630
18.

The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.

Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, Jorgensen A, Payne K, Pirmohamed M, Pushpakom S, Walley T, de Warren-Penny P, Dickson R.

Health Technol Assess. 2010 Jan;14(3):1-157, iii. doi: 10.3310/hta14030. Review.

19.

Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.

Chue PS, Heeg B, Buskens E, van Hout BA.

Pharmacoeconomics. 2005;23 Suppl 1:62-74.

PMID:
16416762
20.

A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.

Bridle C, Palmer S, Bagnall AM, Darba J, Duffy S, Sculpher M, Riemsma R.

Health Technol Assess. 2004 May;8(19):iii-iv, 1-187. Review.

Items per page

Supplemental Content

Write to the Help Desk